Stock FBRX FORTE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Forte Biosciences, Inc.

Equities

FBRX

US34962G1094

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-04-26 EDT 		5-day change 1st Jan Change
0.7163 USD -3.07% Intraday chart for Forte Biosciences, Inc. -2.41% -12.83%
03-18 Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01-05 Camac Partners Provides Information to Shareholders CI

Evolution of the average Target Price on Forte Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7aa088d379d1.a_19eWjHC9fnsuUxsabeLLQd2e59ltH4xJRSMvUnfsA.NLkSTDrzRqbT9IdD_p_saP5n7pkE1OacqMQwe7cKLJIomUsyOaQ8srD7rA~878ff20faa758b3c14012e43dee47576

Analyst Recommendations on Forte Biosciences, Inc.

FORTE BIOSCIENCES : Chardan Capital Upgrades Forte Biosciences to Neutral From Sell Following Recent Selloff, Adjusts Price Target to $3.50 From $4 MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral From Buy MT
FORTE BIOSCIENCES : Brookline Capital Downgrades Forte Biosciences to Hold from Buy MT
FORTE BIOSCIENCES : Chardan Downgrades Forte Biosciences to Sell From Buy, Adjusts Price Target to $4 From $105; Shares Slide 80% Premarket MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral from Buy MT
FORTE BIOSCIENCES : B. Riley Downgrades Forte Biosciences to Neutral from Buy After Lead Program FB-401 Failed to Strike Primary Endpoint, Lowers PT to $3 from $73 MT
FORTE BIOSCIENCES : Truist Securities Downgrades Forte Biosciences to Hold from Buy MT
FORTE BIOSCIENCES : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says FB-401 Could Fill Gap for Steroid-Free Treatment for Atopic Dermatitis MT
FORTE BIOSCIENCES : Citigroup Starts Forte Biosciences at Buy With $75 Price Target MT
FORTE BIOSCIENCES : Chardan Capital Adjusts Price Target on Forte Biosciences to $105 From $115, Maintains Buy Rating MT
FORTE BIOSCIENCES : Chardan Adjusts Forte Biosciences' Price Target to $115 From $110, Keeps at Buy MT
Forte Biosciences : Shares Higher After Truist Initiates Coverage DJ
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7163 USD
Average target price
2.875 USD
Spread / Average Target
+301.37%
High Price Target
3 USD
Spread / Highest target
+318.82%
Low Price Target
2.75 USD
Spread / Lowest Target
+283.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Forte Biosciences, Inc.

Chardan
Brookline Capital Management
Ladenburg Thalmann
Truist Securities
B. Riley
Citigroup

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. FBRX Stock
  4. Consensus Forte Biosciences, Inc.